<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN"
       "https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" dtd-version="1.3" article-type="case-report" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="nlm-ta">Ulutas Med J</journal-id>
   <journal-title-group>
    <journal-title>The Ulutas Medical Journal</journal-title>
    <abbrev-journal-title>Ulutas Med J</abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="ppub">2149-0430</issn>
   <issn pub-type="epub">2149-388X</issn>
   <publisher>
    <publisher-name>Hayriye Zehra Ulutaş</publisher-name>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="doi">10.5455/umj.20180123053002</article-id>
   <article-id pub-id-type="publisher-id">289039</article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>Case Report</subject>
    </subj-group>
    <subj-group subj-group-type="subject">
     <subject>Cancer</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title>Metastatic Adrenocortical Carcinoma of the Lung In A Four Years Old Child</article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" corresp="yes">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0566-0369</contrib-id>
     <name name-style="western">
      <surname>Alobaid</surname>
      <given-names>Lulu Abdulaziz</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff1">1</xref>
    </contrib>
    <contrib contrib-type="author">
     <name name-style="western">
      <surname>Jafari</surname>
      <given-names>Ilhama</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff2">2</xref>
    </contrib>
    <contrib contrib-type="author">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9036-7564</contrib-id>
     <name name-style="western">
      <surname>Almosallam</surname>
      <given-names>Osama</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff3">3</xref>
    </contrib>
    <contrib contrib-type="author">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-8758-2347</contrib-id>
     <name name-style="western">
      <surname>Rahman</surname>
      <given-names>Muhammed Amin ur</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff4">4</xref>
    </contrib>
    <contrib contrib-type="author">
     <name name-style="western">
      <surname>Aljubab</surname>
      <given-names>Abdulwahhab</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff5">5</xref>
    </contrib>
    <aff id="aff1">
     <label>1</label>
     <institution-wrap>
      <institution-id institution-id-type="ror">https://ror.org/02f81g417</institution-id>
      <institution>Medical intern at King Saud University, Riyadh, Saudi Arabia</institution>
     </institution-wrap>
    </aff>
    <aff id="aff2">
     <label>2</label>
     <institution-wrap>
      <institution-id institution-id-type="ror">https://ror.org/01jgj2p89</institution-id>
      <institution>Associate Consultant at Pediatric Surgery at King Fahad Medical City, Riyadh, Saudi Arabia</institution>
     </institution-wrap>
    </aff>
    <aff id="aff3">
     <label>3</label>
     <institution-wrap>
      <institution-id institution-id-type="ror">https://ror.org/01wsfe280</institution-id>
      <institution>Fellow at Pediatric Surgery department at Qassim University, Qassim, Saudi Arabia</institution>
     </institution-wrap>
    </aff>
    <aff id="aff4">
     <label>4</label>
     <institution-wrap>
      <institution-id institution-id-type="ror">https://ror.org/01jgj2p89</institution-id>
      <institution>Histopathologist at King Fahad Medical City, Riyadh, Saudi Arabia.</institution>
     </institution-wrap>
    </aff>
    <aff id="aff5">
     <label>5</label>
     <institution-wrap>
      <institution-id institution-id-type="ror">https://ror.org/01jgj2p89</institution-id>
      <institution>Consultant at Pediatric Surgery at King Fahad Medical City, Riyadh, Saudi Arabia</institution>
     </institution-wrap>
    </aff>
   </contrib-group>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2018-03-28">
    <day>28</day>
    <month>03</month>
    <year>2018</year>
   </pub-date>
   <pub-date publication-format="print" date-type="collection">
    <year>2018</year>
   </pub-date>
   <volume>4</volume>
   <issue>1</issue>
   <fpage>38</fpage>
   <lpage>43</lpage>
   <history>
    <date date-type="received" iso-8601-date="2018-01-03">
     <day>03</day>
     <month>01</month>
     <year>2018</year>
    </date>
    <date date-type="rev-recd" iso-8601-date="2018-02-24">
     <day>24</day>
     <month>02</month>
     <year>2018</year>
    </date>
    <date date-type="accepted" iso-8601-date="2018-03-21">
     <day>21</day>
     <month>03</month>
     <year>2018</year>
    </date>
   </history>
   <permissions>
    <copyright-statement>© 2018 The Author(s)</copyright-statement>
    <copyright-year>2018</copyright-year>
    <license>
     <ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
     <license-p>This is an open access article distributed under the CC BY-NC 4.0 licence.</license-p>
    </license>
   </permissions>
   <self-uri xlink:href="https://www.ulutasmedicaljournal.com/?mno=289039"/>
   <self-uri content-type="pdf" xlink:href="https://www.ulutasmedicaljournal.com/pdf/289039.pdf"/>
   <abstract>
    <p>Background: Studies of adrenocortical carcinoma is an aggressive rare type of endocrine tumors. It possesses a high mortality rate. This type of carcinomas occurs sporadically, while it could be part of hereditary syndromes. Only limited data is found about the recurrence of these tumors after resection and their prognosis is unclear. Case Presentation: We present a case of a four-year-old boy who presented with virilization symptoms and was referred for further investigation of left abdominal mass. He was cushingoid upon examination. The patient was managed by left nephrectomy and chemotherapy. Upon follow up, the residual mass lesion was seen on CT. Re-resection of the residual tumor was done. Adjuvant mitotane therapy and radiotherapy were started, 7 months later the patient was discovered to have left lung metastasis in which he underwent left lung wedge resection.</p>
   </abstract>
   <kwd-group kwd-group-type="author">
    <kwd>Adrenocortical tumors</kwd>
    <kwd>adrenocortical carcinoma</kwd>
    <kwd>lung metastasis</kwd>
   </kwd-group>
   <funding-group>
    <funding-statement>Funding information was not reported in the published version of this article.</funding-statement>
   </funding-group>
  </article-meta>
 </front>
 <body>
  <sec id="sec-1">
   <title>Introduction</title>
   <p id="b-1">Adrenocortical tumors are rare in children, while adrenocortical carcinoma is even more uncommon in this age group (    <xref ref-type="bibr" rid="ref1">1</xref>
). Although ACC is rare but it’s one of the aggressive types of endocrine tumors (    <xref ref-type="bibr" rid="ref2">2</xref>
). It has been reported by its tragic high mortality rate(    <xref ref-type="bibr" rid="ref3">3</xref>
,    <xref ref-type="bibr" rid="ref4">4</xref>
). The worldwide annual incidence of ACT is only 0.3 - 0.38 per million children below the age of 15 years (    <xref ref-type="bibr" rid="ref5">5</xref>
,    <xref ref-type="bibr" rid="ref6">6</xref>
). Commonly adrenocortical carcinoma occurs sporadically. It could also present as part of hereditary syndromes like Li-Fraumeni syndrome and Beckwith-Wiedemann syndrome (    <xref ref-type="bibr" rid="ref7">7</xref>
,    <xref ref-type="bibr" rid="ref8">8</xref>
), in children with genetic predisposition (R337H mutation) like in south Africa where its prevalence is more than three times higher than other areas (    <xref ref-type="bibr" rid="ref6">6</xref>
).</p>
   <p id="b-2">The peak incidence of ACC is between the fourth and fifth decades, although it can occur in all age groups (    <xref ref-type="bibr" rid="ref2">2</xref>
). Females have slight predominance (    <xref ref-type="bibr" rid="ref9">9</xref>
). Lung metastasis have been reported with ACC (    <xref ref-type="bibr" rid="ref10">10</xref>
).</p>
   <p id="b-3">In this report, we present a case of a 4-yearold boy with metastatic left adrenocortical carcinoma. Lung metastasis have occurred almost 7 months after the primary tumor resection. The study was approved by Institutional Review Board At King Fahad Medical City in Riyadh, Saudi Arabia.</p>
  </sec>
  <sec id="sec-2">
   <title>Case Presentation</title>
   <p id="b-4">Four years old Sudanese boy was referred for further management of left abdominal mass. Symptoms started 2 months prior to presentation, when he developed acne mainly in the forehead involving scalp, weight gain, increase in appetite, gradual increase in the abdominal girth, penile enlargement with pubic hair, change in sweat smell (adult odor), fatigability, mild on and off abdominal pain, urinary frequency and behavioral changes. There was no family history of tumors or cancers. The mother underwent thyroidectomy due to goiter with hypothyroidism. On examination, he was vitally stable with cushingoid features, rounded face with pudgy cheeks (Moon face), penile enlargement with pubic hair but no facial hair.</p>
   <p id="b-5">The abdomen was distended without any tenderness. Palpable mass was noted in the left side of the abdomen. Otherwise normal examination with clear chest. CT of abdomen showed a large circumscribed left flank heterogeneous soft tissue lesion measuring 10x9x11 cm, which caused displacement of the surrounding vas-cular structure with no evidence of encasement. There was displacement of the left kidney inferiorly, with no evidence of liver, lung, or osseous metastasis, and no intra-spinal extension. Laboratory work up showed high plasma LDH level (Almost triple the normal), low plasma ACTH level, normal serum cortisol and total testosterone levels, high serum dehydro epiandrosterone sulfate levels. The case was discussed in multidisciplinary tumor board meeting and the plan was operative resection. Up-front surgical resection plus left nephrectomy 26.5.2016 was done with fragile tumor spillage intraopera-tively. Irrigation and suction was done. The tumor was involving the upper pole of the kidney and it was inseparable from the renal parenchyma (Figure-1) so the decision was to do radical nephrectomy in addition to adrenalectomy to reduce the chance of recurrence. Post-operative course was uneventful. Pathologic examination of the primary tumor revealed multinodulated white tan mass measuring 10x8x4 cm replacing most of the kidney parenchyma and reaching to the renal sinus and perinephric fat grossly. No adrenal gland was identified grossly. Tumor was not reaching the vascular margins and no lymph nodes identified in the hilar fat.</p>
   <fig id="fig-1" position="float">
    <label>Figure 1</label>
    <caption>
     <p>Intraoperative primary tumor</p>
    </caption>
    <graphic xlink:href="fig-1.png">
     <alt-text>Figure 1: Intraoperative primary tumor</alt-text>
    </graphic>
   </fig>
   <p id="b-6">Under microscope, the tumor showed diffused proliferation of highly pleomorphic epithelioid cells seen as sheets and nests with highly pleomorphic and bizzar nuclei with some multinucleated cells. Cells show abundant eosi-nophilic granular cytoplasm. Clear cells change was seen in about 10% of tumor. Mitoses were brisk with many atypical mitoses no-ted (Figure-2). Necrosis was prominent (Figure-3). Vascular invasion near the capsule was also noted. However, the renal vein and arterial vas-cular margins were clear. The tumor appeared to have pushing borders at the tumor-kidney interface and didn’t show any evidence of invasion into the renal parenchyma (Figure-4). On immunohistochemistry, the tumor was positive with Vimentin, Melanen A and Synap-tophysin and was negative with Cytokeratin, EMA (Only focally positive), Inhibin, Calretinin, S100,Chromnogranin,and CD56 (which showed very focal positive). This immunoprofile was in keeping with adrenal cortical tumor. Although negative staining with both inhibin and calretinin is unusual, but it can rarely be seen in adrenal cortical neoplasma. MelanA positivity is helpful for the diagnosis. The diagnosis was agreed on by two independent pathologists. Post-operative follow-up CT scan 10 days after surgery showed interval resection of the large left suprarenal mass and left kidney, small enhancing soft tissue seen in the left paravertebral region, could be residual tumor or peritoneal deposits. With no evidence of chest metastasis. The patient underwent chemotherapy COG (ARAR0332 protocol). He had four cycles with poor response, rather suggestive of tumor progression on chemotherapy with rising DHEA levels.</p>
   <fig id="fig-2" position="float">
    <label>Figure 2</label>
    <caption>
     <p>Atypical mitosis</p>
    </caption>
    <graphic xlink:href="fig-2.png">
     <alt-text>Figure 2: Atypical mitosis</alt-text>
    </graphic>
   </fig>
   <fig id="fig-3" position="float">
    <label>Figure 3</label>
    <caption>
     <p>Areas of necrosis</p>
    </caption>
    <graphic xlink:href="fig-3.png">
     <alt-text>Figure 3: Areas of necrosis</alt-text>
    </graphic>
   </fig>
   <fig id="fig-4" position="float">
    <label>Figure 4</label>
    <caption>
     <p>Kidney tumor interface shows intact kidney surface</p>
    </caption>
    <graphic xlink:href="fig-4.png">
     <alt-text>Figure 4: Kidney tumor interface shows intact kidney surface</alt-text>
    </graphic>
   </fig>
   <p id="b-7">CT chest, abdomen and pelvis three months after, showed Residual well demarcated predominantly hypodense soft tissue mass lesion no-ted in the left renal/adrenal region measures 3.9x2.3x3cm most likely representing local residual. In the chest satisfactory position of the left central line, no hilar lymphadenopathy. Both lungs are within normal limits with no suspicious pulmonary nodules.</p>
   <table-wrap id="tbl-1" position="float">
    <label>Table 1</label>
    <caption>
     <title>Weiss system and Modified Weiss system.</title>
    </caption>
    <graphic xlink:href="tbl-1.png">
     <alt-text>Table 1: Weiss system and Modified Weiss system.</alt-text>
    </graphic>
   </table-wrap>
   <p id="b-8">Macroscopic re-resection of the residual tumor was done 4 months after the primary resection, where the mass was identified, separated from medial aspect of IVC and was dissected with no evidence of tumor residual. Pathologic examination showed residual viable tumor, positive regional lymph node, no chemotherapy changes and invasion of fibro-fatty soft tissue (stage 3). Clinically he was doing fine with no virilization symptoms. 11 days post re-resection abdomen/pelvis CT showed, the previously seen left paraspinal left tissue residual mass lesion has been surgically resected. A focal area of enhancing soft tissue is seen in the tumor bed. There is another focal hypodense mass lesion measures 15x21 mm seen in the left prevertebral compartment abutting the posterior wall of the splenic artery. Adjuvant oral mitotane therapy and local radiotherapy were initiated. Follow up CT, 3 months after, revealed subtle reduction in size of the residual mass. The residual soft tissue seen in the left adrenal gland bed is demonstrated showing more enhancing component, it roughly measures 12x10 cm as compared to 22x12 mm done 3 months back. CT chest showed interval development of a lung nodule seen in the lingual measuring 5.6x5.3 mm. No major airspace consolidation or collapse. No pleural effusion or pneumothorax. The major tracheobronchial tree is patent. No size significant axillary, mediastinal or hilar lymph nodes. There’s evidence of a small enhancing nodule close to the posterior left 11    <sup>th</sup>
 rib measuring 12x6 mm suggestive of another metastatic nodule.</p>
   <p id="b-9">The patient hadmetastatic adrenocortical carcinoma to the left lung, underwent left lung wedge resection. Pathology showed residual microscopic focus of metastatic adrenocarcinoma 5%, Resection margin negative for tumor, he was started on radiotherapy to the left lung surgical bed.</p>
   <p id="b-10">Whole body PET scan, FDG avid left paraaortic nodules as well as left chest well solitary nodule measuring 1.1x1 cm. The rest of the body showed no suspicious FDG uptake. A week after, MRI chest on showed enhanced lesion in 11    <sup>th</sup>
 intercostal space seen in the post contrast coronal T1- weighted image measures 1.2x0.7 cm. The lesion shows high signal intensity in coronal STIR weighted image and isointensity in coronal T1-weighted image.</p>
  </sec>
  <sec id="sec-3">
   <title>Discussion</title>
   <p id="b-11">Adrenocortical carcinoma is known by its rarity since it represents only 0.2% of all childhood cancers(    <xref ref-type="bibr" rid="ref7">7</xref>
).The diagnosis ofadrenocortical neoplasm in children is usually made as a result of symptoms caused by hormonal production by the cancer cells (    <xref ref-type="bibr" rid="ref11">11</xref>
). In this case, the cushingoid features and sexual precocity drove the discovery of the mass, which was investigated and the tumor was found subsequently. Left sided ACC are generally more common than right side, as in our case (    <xref ref-type="bibr" rid="ref12">12</xref>
). Carcinoma can’t be distinguished from an adenoma from patient presentation, even in the presence of laboratory findings and imaging studies. Although large tumor size in imaging and heterogeneity can predict carcinomas (    <xref ref-type="bibr" rid="ref13">13</xref>
). Categorization of carcinoma from adenoma in adrenocortical pathology is challenging. In 1989 the introduction of Weiss criteria was adopted to differentiate carcinoma from adenoma. This has been modified in 2002 as ‘modified Weiss system’ and is now the preferred modality to be used (    <xref ref-type="bibr" rid="ref14">14</xref>
). In this case we used the modified Weiss system (Table-1). Presence of atypical mitoses, clear cells comprising around 10 % of the tumor and necrosis would put our patient in 62% 5 years survival rate. Larger tumor size, high percent necrosis and high mitotic rate are associated with poor outcome (    <xref ref-type="bibr" rid="ref15">15</xref>
). Margin status of the tumor, extension of tumor outside the adrenal gland, presence of metastasis and age were associated with worst survival (    <xref ref-type="bibr" rid="ref16">16</xref>
,    <xref ref-type="bibr" rid="ref17">17</xref>
). Using TNM staging system (Table-2) (    <xref ref-type="bibr" rid="ref18">18</xref>
) prior the re-resection our patient was thought to be stage 2. Afterward, he was discovered to have stage 3 cancer. Post-radical resection of ACC, adjuvant mitotane could lengthen recurrence free survival period (    <xref ref-type="bibr" rid="ref19">19</xref>
). In addition, radiotherapy is recommended in cases with high risk of local recurrence (    <xref ref-type="bibr" rid="ref2">2</xref>
). Therefore, adjuvant mitotane therapy and local radiotherapy were initiated. Whereas, the 13 institutions study concluded that there’s no association between adjuvant mitotane after resection and improvement of recurrence-free survival or overall survival (    <xref ref-type="bibr" rid="ref20">20</xref>
). Our patient developed lung metastasis while on mitotane therapy. In a series study done in Turkey, out of 20 ACC patients, 3 had lung metastasis at presentation in which one of them had concurrence liver metastasis. Furthermore, during mitotane therapy within 2 years’ time, 3 patients developed lung and liver metastasis, while another 2 patients developed lung and bone metastasis. They have stated that (frequent imaging studies and endocrine evaluation was of utmost importance to detect recurrence in long-term follow-up of patients)(    <xref ref-type="bibr" rid="ref10">10</xref>
).</p>
  </sec>
  <sec id="sec-4">
   <title>Conclusion</title>
   <p id="b-12">Adrenocortical carcinoma is a rare neoplasm in children, it has a high mortality rate. Lung metastasis could occur after tumor resection even after initiation of mitotane and local radiotherapy.</p>
  </sec>
 </body>
 <back>
  <ref-list>
   <title>References</title>
   <ref id="ref1">
    <label>1</label>
    <mixed-citation publication-type="journal">Breidbart E, Cameo T, Garvin JH, Hibshoosh H, Oberfield SE. Pubertal outcome in a female with virilizing adrenocortical carcinoma. J Pediatr Endocrinol Metab. 1 styczeń 2016;29(4): 503–9.</mixed-citation>
   </ref>
   <ref id="ref2">
    <label>2</label>
    <mixed-citation publication-type="journal">Fassnacht M, Kroiss M, Allolio B. Update in Adrenocortical Carcinoma. J Clin Endocrinol Metab. grudzień 2013;98(12): 4551–64.</mixed-citation>
   </ref>
   <ref id="ref3">
    <label>3</label>
    <mixed-citation publication-type="journal">Stewart DR, Morris Jones PH, Jolleys A. Carcinoma of the adrenal gland in children. J Pediatr Surg. luty 1974 [cytowane 30 wrzesień 2016];9(1):59–67.</mixed-citation>
   </ref>
   <ref id="ref4">
    <label>4</label>
    <mixed-citation publication-type="journal">Zaitoon MM, Gary Mackie G. Adrenal cortical tumors in children. Urology. grudzień 1978 [cytowane 30 wrzesień 2016]; 12(6):645–9.</mixed-citation>
   </ref>
   <ref id="ref5">
    <label>5</label>
    <mixed-citation publication-type="journal">Hisada M, Garber JE, Li FP, Fung CY, Fraumeni JF. Multiple Primary Cancers in Families With Li-Fraumeni Syndrome. JNCI J Natl Cancer Inst. 15 kwiecień 1998;90(8):606–11.</mixed-citation>
   </ref>
   <ref id="ref6">
    <label>6</label>
    <mixed-citation publication-type="journal">Stiller CA. International variations in the incidence of childhood carcinomas. Cancer Epidemiol Biomarkers; 1994; 3(4):305 LP-310.</mixed-citation>
   </ref>
   <ref id="ref7">
    <label>7</label>
    <mixed-citation publication-type="journal">Ribeiro RC, Figueiredo B. Childhood adrenocortical tumours. Eur J Cancer. maj 2004 [cytowane 30 wrzesień 2016]; 40(8):1117–26. Metastatic Adrenocortical Carcinoma Alobaid, et al.</mixed-citation>
   </ref>
   <ref id="ref8">
    <label>8</label>
    <mixed-citation publication-type="journal">Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcino genesis. Mol Cell Endocrinol [Internet]. marzec 2012 [cytowane 1 październik 2016];351(1):101–10.</mixed-citation>
   </ref>
   <ref id="ref9">
    <label>9</label>
    <mixed-citation publication-type="journal">Patil KK, Ransley PG, McCullagh M, Malone M, Spitz L. Functioning adrenocortical neoplasms in children. BJU Int. 9 kwiecień 2002 [cytowane 1 październik 2016];89(6):562–5.</mixed-citation>
   </ref>
   <ref id="ref10">
    <label>10</label>
    <mixed-citation publication-type="journal">Ciftci BAO, Tanyel FC, Bu N. Adrenocortical Tumors in Children. 2001;36(4):549–54.</mixed-citation>
   </ref>
   <ref id="ref11">
    <label>11</label>
    <mixed-citation publication-type="journal">Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer. 1 grudzień 1993;72(11):3145–55.</mixed-citation>
   </ref>
   <ref id="ref12">
    <label>12</label>
    <mixed-citation publication-type="journal">Srinivas K. Adrenocortical Tumors in Children. J Evol Med Dent Sci. 29 sierpień 2015;4(70):12184–6.</mixed-citation>
   </ref>
   <ref id="ref13">
    <label>13</label>
    <mixed-citation publication-type="journal">Wolthers OD, Cameron FJ, Scheimberg I, Honour JW, Hindmarsh PC, Savage MO. Androgen secreting adreno cortical tumours. Arch Dis Child. styczeń 1999;80(1):46–50.</mixed-citation>
   </ref>
   <ref id="ref14">
    <label>14</label>
    <mixed-citation publication-type="journal">Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. czerwiec 2009;40(6):757–68.</mixed-citation>
   </ref>
   <ref id="ref15">
    <label>15</label>
    <mixed-citation publication-type="journal">Klein JD, Turner CG, Gray FL, Yu DC, Kozakewich HP, Perez-Atayde AR. Adrenal cortical tumors in children: factors associated with poor outcome. J Pediatr Surg. czerwiec 2011;46(6):1201–7.</mixed-citation>
   </ref>
   <ref id="ref16">
    <label>16</label>
    <mixed-citation publication-type="journal">Gulack BC, Rialon KL, Englum BR, Kim J, Talbot LJ, Adibe OO. Factors associated with survival in pediatric adrenocortical carcinoma: An analysis of the National Cancer Data Base (NCDB). J Pediatr Surg. styczeń 2016;51(1):172–7.</mixed-citation>
   </ref>
   <ref id="ref17">
    <label>17</label>
    <mixed-citation publication-type="journal">McAteer JP, Huaco JA, Gow KW. Predictors of survival in pediatric adrenocortical carcinoma: A Surveillance, Epide-miology, and End Results (SEER) program study. J Pediatr Surg. 30 maj 2013;48(5):1025–31.</mixed-citation>
   </ref>
   <ref id="ref18">
    <label>18</label>
    <mixed-citation publication-type="journal">Union for International Cancer Control. The TNM Classification of Malignant Tumours. 7 th Editio. Gospodaro wicz M, Wittekind Christian, Leslie S, redaktorzy. 2009.</mixed-citation>
   </ref>
   <ref id="ref19">
    <label>19</label>
    <mixed-citation publication-type="journal">Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356.</mixed-citation>
   </ref>
   <ref id="ref20">
    <label>20</label>
    <mixed-citation publication-type="journal">Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, i in. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. J Am Coll Surg. 2016 [cytowane 19 listopad 2016];222(4):480–90. The Ulutas Medical Journal Convenient Online Pdf submission Fast response through peer review No space constraints/color figure charges Immediate publication after acceptance Indexed in CrossREF and Google Scholar To submit your manuscript, please click on https://www.ulutasmedicaljournal.com</mixed-citation>
   </ref>
  </ref-list>
 </back>
</article>
